NYMC Faculty Publications
Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is it Protective?
Author Type(s)
Faculty
Journal Title
Current Breast Cancer Reports
First Page
302
Last Page
308
Document Type
Article
Publication Date
12-1-2013
Abstract
Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic.
Recommended Citation
Bedoschi, G., Turan, V., & Oktay, K. (2013). Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is it Protective?. Current Breast Cancer Reports, 5 (4), 302-308. Retrieved from https://touroscholar.touro.edu/nymc_fac_pubs/5741
